Structure Therapeutics Inc. Sponsored ADR (GPCR)
(Delayed Data from NSDQ)
$34.49 USD
+0.46 (1.35%)
Updated Aug 8, 2024 04:00 PM ET
After-Market: $34.50 +0.01 (0.03%) 5:26 PM ET
3-Hold of 5 3
C Value D Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$34.49 USD
+0.46 (1.35%)
Updated Aug 8, 2024 04:00 PM ET
After-Market: $34.50 +0.01 (0.03%) 5:26 PM ET
3-Hold of 5 3
C Value D Growth D Momentum F VGM
Zacks News
What's in Store for Structure Therapeutics (GPCR) in Q2 Earnings?
by Zacks Equity Research
Structure Therapeutics (GPCR) is expected to provide updates on the developmental pathway of its lead product candidate, GSBR-1290, for diabetes and obesity indications in the Q2 earnings release.
Structure Therapeutics (GPCR) Rallying on Obesity Drug Data
by Zacks Equity Research
Structure Therapeutics (GPCR) stock sees an upside on positive top-line data from a phase IIa obesity study as well as a capsule-to-tablet PK study on its obesity candidate, GSBR-1290.
Structure Therapeutics (GPCR) Stock Up 9% This Week: Here's Why
by Zacks Equity Research
Structure Therapeutics (GPCR) rises 9% on encouraging initial data from the early-stage study of its pipeline candidate, GSBR-1290, in healthy overweight or obese individuals.
IPO Round Up of First Half of 2023
by Sanghamitra Saha
Normally, IPO activity gains momentum in the second quarter and peaks in June. This year was no exception.